An ad hoc committee will plan and conduct a 1-day public workshop to examine and discuss how large-scale genetic data could be used to improve the likelihood of bringing effective and targeted therapies to patients. The goal of the workshop will be to address how progress could be made in discovering and validating promising targets and medicines for those targets by using the data collected from large-scale genetic studies. Discussions will be held with a broad array of stakeholders, which may include representatives from pharmaceutical and biotech companies, information technology and data science companies, research institutes, investors, providers, patients, payers, and regulators. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and moderate the discussions. A summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.
This page intentionally left blank.